國家衛生研究院 NHRI:Item 3990099045/10527
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 857860      Online Users : 652
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/10527


    Title: Meglitinides increase the risk of hypoglycemia in diabetic patients with advanced chronic kidney disease: A nationwide, population-based study
    Authors: Wu, PC;Wu, VC;Lin, CJ;Pan, CF;Chen, CY;Huang, TM;Wu, CH;Chen, L;Wu, CJ;Consortium, The NRPB Kidney
    Contributors: Division of Health Services and Preventive Medicine
    Abstract: The safety of short-acting meglitinides in diabetic patients with advanced chronic kidney disease (CKD) has not been widely reported.Diabetic patients with advanced CKD who had a serum creatinine level of > 6 mg/dL a hematocrit level of <== 28% and received erythropoiesis-stimulating agent treatment between 2000 and 2010, were included in this nationwide study in Taiwan.The outcomes of interest were defined as hypoglycemia and long-term mortality. The risks of hypoglycemia and death were analyzed using Cox proportional hazards models, with end-stage renal disease and anti-diabetic drugs as time-dependent variables.Fresh users and matched non-users of meglitinides (both n = 2,793) were analyzed. The use of meglitinides increased the risk of hypoglycemia (HR, 1.93; 95% CI, 1.56-2.39), as did sulfonylurea and insulin use. The hypoglycemic effect of meglitinides was consistent among patient subgroups stratified by the status of concomitant use of other oral anti-diabetic agents. Concomitant use of meglitinide and insuilin will incresase the hypoglycemic risk. Moreover, it was not the use of meglitinides, but the presence of hypoglycemia that predicted mortality. The function curve showed an insignificant trend towards increased hypoglycemic risk in patients aged > 62 and </= 33 years from the generalized additive model.This study suggests that the use of short-acting meglitinides could be associated with increased risk of hypoglycemia in diabetic patients with advanced CKD, especially in patients aged > 62 and </= 33 years. Meglitinide combined with insulin will increase hypoglycemia in patients with advanced CKD.
    Date: 2017-09
    Relation: Oncotarget. 2017 Sep;8(44):78086-78095.
    Link to: https://doi.org/10.18632/oncotarget.17475
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000412066700183
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85030309241
    Appears in Collections:[Li-Kwang Chen] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB28514729.pdf1070KbAdobe PDF326View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback